Search

Savara Inc

Lezárt

SzektorEgészségügy

4.73 -2.27

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

4.74

Maximum

5.01

Fő mutatók

By Trading Economics

Bevétel

-2.9M

-40M

Egy részvényre jutó nyereség

-0.16

Munkavállalók

70

EBITDA

-2.9M

-40M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+131.4% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 10.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-182M

992M

Előző nyitás

7

Előző zárás

4.73

Savara Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. okt. 13. 20:13 UTC

Savara Inc shares advanced in after-market trading, continuing their upward trend since Tuesday's close, though still below the 20-day moving average.

2026. okt. 12. 19:36 UTC

Social Media

Savara Inc shares are declining, having pulled back from an earlier high in pre-market hours, and are currently below their 20-day moving average.

2026. okt. 9. 19:55 UTC

Social Media

JPMorgan sets a price target of $12 for Savara Inc, noting catalysts including anticipated UK approval in Q4 and a MAA in Q1 for molgramostim.

2026. okt. 8. 23:25 UTC

Savara Inc shares advanced during after-market hours on Thursday, settling at a solid gain.

2026. okt. 7. 20:01 UTC

News
Social Media

Savara Inc shares are trading sharply higher as JP Morgan initiated coverage with an Overweight rating and a $12 price target ahead of its PDUFA date.

2026. okt. 6. 20:00 UTC

Savara Inc shares fell, breaking a trend of higher daily closes, indicating a shift in momentum following Monday's close.

2026. okt. 2. 20:01 UTC

Savara Inc shares fell sharply, experiencing significant volatility and trading below their 20-day moving average amid high market volume.

2026. okt. 1. 19:46 UTC

Social Media

Savara Inc shares are trading lower as heightened short interest and increased volume coincide with the approach of its PDUFA date for molgramostim.

2026. szept. 30. 21:03 UTC

Social Media

Savara Inc shares are trading higher in after-market hours amid speculation of a short squeeze ahead of its PDUFA date for molgramostim, with a market cap of $1 billion.

2026. szept. 28. 20:02 UTC

Social Media

Savara Inc is trading higher amid notable social media activity and unusual options bets, with a PDUFA date set for November 22.

2026. szept. 25. 20:07 UTC

Savara Inc shares fell sharply, continuing the downward trend with a cumulative return in negative territory and remaining below its 20-day moving average.

2026. szept. 24. 19:46 UTC

Savara Inc is trading higher, having previously peaked before a slight retracement, though it remains below its 20-day moving average.

2026. szept. 23. 22:01 UTC

Savara Inc gained in after-market trading following a brief decline earlier in the session, though it remains below its 20-day moving average.

2026. szept. 22. 20:05 UTC

Savara Inc's stock is declining sharply, moving from an initial gain to a notable drop, trading below its 20-day moving average.

2026. szept. 21. 20:12 UTC

Savara Inc is advancing in after-market trading, positioned above its 20-day moving average and near the upper end of its one-month range.

2026. szept. 18. 23:11 UTC

Savara Inc is trading modestly higher in after-market hours, reflecting the broader market's upward movement, with notable gains since Friday's close.

2026. szept. 17. 23:11 UTC

Savara Inc is seeing a modest upward move in after-market trading, currently near the upper end of its one-month range.

2026. szept. 16. 20:10 UTC

Savara Inc shares fell sharply today, continuing a decline since Tuesday and trading significantly below its 20-day moving average.

2026. szept. 15. 20:07 UTC

Savara Inc shares are lower, impacted by a sharp decline in the NY Empire State Manufacturing Index and rising oil prices amid broader market weakness.

2026. szept. 11. 20:08 UTC

Savara Inc. shares are trading lower today, continuing a decline since Thursday's close amid a broader market downturn.

2026. szept. 10. 20:03 UTC

Savara Inc. shares are lower today, reflecting broader market conditions amid the European Central Bank's recent interest rate hike and inflation projections.

2026. szept. 4. 19:26 UTC

Savara Inc shares are higher today, trading within a narrow range. The stock is currently near the lower end of its one-month range.

2026. szept. 3. 20:02 UTC

Savara Inc shares are lower during Thursday's session, retracing from an earlier peak amid rising jobless claims that may affect Federal Reserve policy.

2026. szept. 2. 20:08 UTC

Savara Inc. shares are higher today, driven by a significant upward trend in the Biotechnology sub-sector. No specific company news was identified.

2026. szept. 1. 19:36 UTC

Savara Inc. shares are lower today, continuing a decline since Monday. The stock remains below its 20-day moving average amid rising inflation concerns.

2026. aug. 31. 22:01 UTC

Savara Inc. shares rose in after-market trading, advancing since Monday's close, despite earlier pulling back from a session high. No specific news was identified.

2026. aug. 28. 21:02 UTC

In after-market trading, Savara Inc. has increased following a flat start, indicating upward momentum despite remaining below its 20-day moving average.

2026. aug. 27. 23:56 UTC

Savara Inc shares are higher in after-market trading, despite no specific news. Broader market sentiment remains mixed amid ongoing inflation concerns and upcoming Fed guidance.

2026. aug. 25. 19:16 UTC

Event

Savara Inc announced presentations at the ERS Congress, yet shares are trading lower today, reflecting a slight decline since Monday's close.

2026. aug. 24. 22:01 UTC

News

Savara Inc. will present Phase 3 trial results for molgramostim at the European Respiratory Society Congress in 2026. Shares are higher in after-market trading.

Társak összehasonlítása

Árváltozás

Savara Inc Előrejelzés

Célár

By TipRanks

131.4% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 11.2 USD  131.4%

Magas 16 USD

Alacsony 9 USD

5 Wall Street elemző 12 hónapos célárain alapulva a(z)Savara Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

5 ratings

5

Vétel

0

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
help-icon Live chat